"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated ...
3h
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...
The second group, so-called "Constrained Losers," are those hard-to-short stocks that have lost the most over the trailing year. The professors found that these stocks also lag the market, but for a ...
Hims and other telehealth companies make finasteride easy to get and don’t have to disclose side effects in ads.
Founded in 2018, Defiance is at the forefront of ETF innovation. Defiance is a leading ETF issuer specializing in thematic, ...
Meet 10 trailblazing Black women breaking barriers and driving change across sports, business, healthcare, and leadership.
Telehealth personalized care company Hims & Hers shuttered a central part of its dermatology offering, skincare brand Apostrophe, to "simplify" its dermatology offerings and operation | Hims & Hers ...
The brand, which entered Target just two years ago, will no longer accept orders on its website after March 24.
Roller-coaster healthcare stock Hims & Hers Health ( HIMS -1.34%), whose stock got devastated last week by worries that it ...
Four-star-rated analyst Daniel Grosslight at Citi reiterated his Sell rating on Hims & Hers Health (HIMS) stock yesterday, ...
Hims & Hers Health has called time on Apostrophe, its personalised acne treatments business. The San Francisco-based ...
Hims & Hers (NYSE: HIMS) stock is down 50% from its peak earlier this year, but the drop in shares hasn't been driven by deteriorating operations. In fact, the company is growing as fast as ever. In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback